secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001104659-23-040172
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana Therapeutics adopts amended bylaws with universal proxy rule updates
----------------------------------------------------------------------------

- Board adopted Second Amended and Restated Bylaws on March 31, 2023, effective immediately.
- Enhanced disclosure and procedural requirements for stockholder director nominations, aligning with SEC universal proxy rules.
- Requires proof of compliance with Rule 14a-19; non-compliance allows disregarding nominations and votes.
- Limits stockholder nominees to number of directors to be elected; removes stockholder list display during remote meetings.
- Added emergency bylaw provision and other conforming changes to Delaware General Corporation Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923040172/0001104659-23-040172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923040172/tm2311091d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer